NR3C2 and hydrops fetalis: With regard to HF treatments, the majority of patients were taking the appropriate disease‐modifying treatment, as guidelines recommend (86% a renin‐angiotensin system inhibitor, 80% a beta blocker, and half of patients a mineralocorticoid receptor antagonists).15